Page last updated: 2024-11-01

nitrendipine and Prostatic Hyperplasia

nitrendipine has been researched along with Prostatic Hyperplasia in 1 studies

Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.

Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rosenthal, E1
Shapiro, E1
Lepor, H1

Other Studies

1 other study available for nitrendipine and Prostatic Hyperplasia

ArticleYear
Characterization of 1,4, dihydropyridine calcium channel binding sites in the human prostate.
    The Journal of urology, 1990, Volume: 144, Issue:6

    Topics: Binding Sites; Calcium Channel Blockers; Calcium Channels; Humans; In Vitro Techniques; Isradipine;

1990